

Oklahoma Health Care Authority

Drug Utilization Review Board (DUR Board)

Meeting – March 11, 2015 @ 4:00 p.m.

Oklahoma Health Care Authority
4345 N. Lincoln Blvd.
Oklahoma City, Oklahoma 73105

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. Call To Order

- A. Roll Call – Dr. Cothran

Items to be presented by Dr. Muchmore, Chairman:

2. Public Comment Forum

- A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A

- A. February 11, 2015 DUR Minutes – Vote
B. February 11, 2015 DUR Recommendations Memorandum

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

4. Update on Medication Coverage Authorization Unit/FDA Safety Alerts – See Appendix B

- A. Medication Coverage Activity for February 2015
B. Pharmacy Help Desk Activity for February 2015
C. FDA Safety Alerts

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

5. Action Item – Vote to Prior Authorize Lemtrada™ (Alemtuzumab) and Plegridy™ (Peginterferon β-1a) – See Appendix C

- A. College of Pharmacy Recommendations

Items to be presented by Dr. Teel, Dr. Muchmore, Chairman:

6. Action Item – Vote to Prior Authorize Brisdelle® (Paroxetine Mesylate) – See Appendix D

- A. College of Pharmacy Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

7. Action Item – Vote to Prior Authorize Orenitram™ (Trepstinil) and Revatio® (Sildenafil Suspension) – See Appendix E

- A. College of Pharmacy Recommendations

Items to be presented by Dr. Anderson, Dr. Muchmore, Chairman:

8. Action Item – Vote to Prior Authorize Myalept™ (Metreleptin) – See Appendix F

- A. College of Pharmacy Recommendations

Items to be presented by Dr. Anderson, Dr. Muchmore, Chairman:

9. Action Item – Annual Review of Ilaris® (Canakinumab) – See Appendix G

- A. Introduction
- B. Current Prior Authorization Criteria
- C. Utilization of Ilaris® (Canakinumab)
- D. Prior Authorization of Ilaris® (Canakinumab)
- E. Market News and Updates
- F. College of Pharmacy Recommendations
- G. Utilization Details of Ilaris® (Canakinumab)

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

10. 30-Day Notice to Prior Authorize Sylvant™ (Siltuximab) – See Appendix H

- A. Introduction
- B. Sylvant™ (Siltuximab) Product Summary
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

11. Annual Review of Topical Antifungal Medications and 30-Day Notice to Prior Authorize Ecoza™ (Econazole Nitrate), Jublia® (Efinaconazole), and Kerydin™ (Tavaborole) – See Appendix I

- A. Current Prior Authorization Criteria
- B. Utilization of Topical Antifungal Medications
- C. Prior Authorization of Topical Antifungal Medications
- D. Market News and Updates
- E. Product Summaries
- F. College of Pharmacy Recommendations
- G. Utilization Details of Topical Antifungal Medications

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

12. Annual Review of Glaucoma Medications and 30-Day Notice to Prior Authorize Izba® (Travoprost Ophthalmic Solution) – See Appendix J

- A. Current Prior Authorization Criteria
- B. Utilization of Glaucoma Medications
- C. Prior Authorization of Glaucoma Medications
- D. Market News and Updates
- E. Izba® (Travoprost Ophthalmic Solution) Product Summary
- F. College of Pharmacy Recommendations
- G. Utilization Details of Glaucoma Medications

Non-Presentation, Questions Only:

13. Annual Review of Soliris® (Eculizumab) – See Appendix K

- A. Indication
- B. Current Prior Authorization Criteria
- C. Utilization of Soliris® (Eculizumab)
- D. Prior Authorization of Soliris® (Eculizumab)
- E. College of Pharmacy Recommendations
- F. Utilization Details of Soliris® (Eculizumab)

Non-Presentation, Questions Only:

14. Annual Review of Botulinum Toxins – See Appendix L

- A. Current Prior Authorization Criteria
- B. Utilization of Botulinum Toxins
- C. Prior Authorization of Botulinum Toxins
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of Botulinum Toxins

Non-Presentation, Questions Only:

15. Annual Review of Singulair® (Montelukast) and Zyflo CR® (Zileuton Extended-Release) – See Appendix M

- A. Introduction
- B. Current Prior Authorization Criteria
- C. Utilization of Singulair® (Montelukast) and Zyflo CR® (Zileuton Extended-Release)
- D. Prior Authorization of Singulair® (Montelukast) and Zyflo CR® (Zileuton Extended-Release)
- E. Market News and Updates
- F. College of Pharmacy Recommendations
- G. Utilization Details of Singulair® (Montelukast) and Zyflo CR® (Zileuton Extended-Release)

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman:

16. FDA and DEA Updates – See Appendix N

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman:

17. Future Business

- A. Annual Reviews
- B. New Product Reviews

Items to be presented by Dr. Muchmore, Chairman:

18. Adjournment